Caritas Traegergesellschaft Saarbruecken mbH (CTS)
- Address
- lock Available on a paid plan
Caritas Traegergesellschaft Saarbruecken mbH (CTS) - Oncology Research Center
Caritas Traegergesellschaft Saarbruecken mbH (CTS) is a comprehensive oncology research center specializing in advanced cancer therapeutics and novel treatment approaches. The center demonstrates particular expertise in breast cancer research, with extensive involvement in trials investigating hormone receptor-positive, HER2-negative, and triple-negative breast cancer subtypes, as well as innovative neoadjuvant and adjuvant immunotherapy combinations.
- Advanced breast cancer trials evaluating targeted therapies, antibody-drug conjugates, and immunotherapy combinations across multiple molecular subtypes
- Gastrointestinal malignancies including colorectal, rectal, pancreatic, and gastroesophageal cancers with focus on personalized treatment strategies
- Hematologic malignancies research encompassing acute myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia
- Gynecologic oncology studies investigating advanced ovarian and endometrial cancers
The center actively participates in Phase II and III clinical trials exploring precision medicine approaches, including genetic marker-guided therapy allocation and circulating tumor DNA monitoring. CTS demonstrates commitment to investigating perioperative immunotherapy strategies, combination therapies with CDK4/6 inhibitors, PARP inhibitors, and novel targeted agents. The research portfolio also includes studies on organ preservation strategies in rectal cancer and biomarker-driven treatment selection in pancreatic adenocarcinoma, reflecting a comprehensive approach to modern oncology research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 96 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 92 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Merck Sharp & Dohme LLC5active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC8trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Caritas Traegergesellschaft Saarbruecken mbH (CTS)
lock Showing 1 of 41 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC) | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Mar 2017 | Oct 2025 |
IMP list
lock Showing 1 of 96 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 12 | Unknown | 2016-11-07 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.